OncoTartis Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6M

  • Investors
  • 5

OncoTartis General Information

Description

Developer of anti-cancer drugs designed to help patients recover from acute leukemia. The company's drug development approach is designed to develop small molecules for the treatment of malignancies originating from specific tissues that are either non-essential for the general viability of mammalian organisms or can be effectively replaced, enabling patients to have access to novel therapies for the treatment of cancer and white cell diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 640 Ellicott Street
  • Suite 480
  • Buffalo, NY 14203
  • United States
+1 (716) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoTartis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 11-Dec-2017 $6M 000.00 Completed Generating Revenue
4. Grant 07-Jun-2017 000.00 00.000 Completed Generating Revenue
3. Grant 00.000 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Jul-2016 $1.85M $8.25M Completed Generating Revenue
1. Early Stage VC (Series A) 17-Feb-2011 $6.4M $6.4M Completed Generating Revenue
To view OncoTartis’s complete valuation and funding history, request access »

OncoTartis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of anti-cancer drugs designed to help patients recover from acute leukemia. The company's drug development app
Drug Discovery
Buffalo, NY
000.00
0000000000 0 000.00

00000

, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis n
0000 000000000
Geneva, Switzerland
00 As of 0000
00000
00000000000 00000

00000

ure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000 000000000
Tucson, AZ
0 As of 0000
00.000
000000000 - 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoTartis Competitors (57)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Light Chain Bioscience Private Equity-Backed Geneva, Switzerland 00 00000 00000000000 00000
00000 000000 Venture Capital-Backed Tucson, AZ 0 00.000 000000000 - 00.000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 000000000 Venture Capital-Backed New York, NY 0 0000 0000000000 0 0000
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
You’re viewing 5 of 57 competitors. Get the full list »

OncoTartis Patents

OncoTartis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2017502960-A Benzamide and nicotinamide compounds and methods of using the same Granted 24-Dec-2013 0000000000 00
ES-2829504-T3 Benzamide and nicotinamide compounds and methods of using them Active 24-Dec-2013 0000000000
US-20190031658-A1 Benzamide and nicotinamide compounds and methods of using same Granted 24-Dec-2013 0000000000
US-10208032-B2 Benzamide and nicotinamide compounds and methods of using same Active 24-Dec-2013 0000000000 0
US-20160347748-A1 Benzamide and nicotinamide compounds and methods of using same Granted 24-Dec-2013 C07D471/04 0
To view OncoTartis’s complete patent history, request access »

OncoTartis Executive Team (6)

Name Title Board Seat Contact Info
Andrei Gudkov Ph.D Co-Founder & Chief Scientific Officer
Aleksandra Kotlyarova Director, Operations
Olga Chernova Ph.D Co-Founder & Vice President, Research
Alexander Polinsky Ph.D Co-Founder & Chief Executive Officer
Eric Rowinsky MD Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

OncoTartis Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Norma Investments Venture Capital Minority 000 0000 000000 0
Pharmstandard Corporation Minority 000 0000 000000 0
Startup Village Government 000 0000 000000 0
Bioprocess Capital Partners Venture Capital Minority 000 0000 000000 0
Skolkovo Foundation Limited Partner 000 0000 000000 0
To view OncoTartis’s complete investors history, request access »